公开(公告)号：US20170049740A1

公开(公告)日：2017-02-23

申请号：US15346926

申请日：2016-11-09

Applicant: ITALFARMACO SPA

Inventor： Tiziano OLDONI ,  Paolo MASCAGNI ,  Alessandro RAMBALDI ,  Tiziano BARBUI

IPC: A61K31/27 ,  A61K45/06

CPC classification number: A61K31/27 ,  A61K31/00 ,  A61K31/16 ,  A61K31/167 ,  A61K31/18 ,  A61K45/06

Abstract: The use of substances capable of inhibiting one or more enzymes of the histone deacetylase family (histone deacetylase inhibitors) for the therapeutic treatment of Philadelphia-negative myeloproliferative syndromes (polycythemia vera, essential thrombocythemia or idiopathic myelofibrosis) is described. The dosage of the above-mentioned substances is significantly lower than that normally used for the care of other tumour syndromes and may be from 10 to 150 mg/day/patient.

Abstract translation: 描述了能够抑制组蛋白脱乙酰酶家族的一种或多种酶（组蛋白脱乙酰酶抑制剂）用于费城阴性骨髓增生综合征（真性红细胞增多症，原发性血小板增多症或特发性骨髓纤维化）的治疗性治疗的物质的使用。 上述物质的剂量明显低于通常用于其他肿瘤综合征的治疗剂量，并且可以为10至150mg /天/患者。

公开(公告)号：US20210128512A1

公开(公告)日：2021-05-06

申请号：US17149794

申请日：2021-01-15

Applicant: ITALFARMACO SPA

Inventor： Tiziano OLDONI ,  Paolo MASCAGNI ,  Alessandro RAMBALDI ,  Tiziano BARBUI

IPC: A61K31/27 ,  A61K31/00 ,  A61K31/16 ,  A61K31/18 ,  A61K31/167 ,  A61K45/06

Abstract: Method of treating Philadelphia-negative myeloproliferative syndromes in a patient suffering therefrom by administering to the patient diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride, or other pharmaceutically acceptable salts and/or solvates, in a daily dosage amount of from 50 to 100 mg per patient.

公开(公告)号：US20190300496A1

公开(公告)日：2019-10-03

申请号：US16315576

申请日：2017-07-14

Applicant: ITALFARMACO SPA

Inventor： Andrea STEVENAZZI ,  Giovanni SANDRONE ,  Daniela MODENA ,  Samuele Pietro POZZI ,  Barbara VERGANI ,  Maria LATTANZIO ,  Paolo MASCAGNI ,  Christian STEINKÜHLER ,  Gianluca FOSSATI

IPC: C07D317/60 ,  C07C259/10 ,  C07D221/04 ,  C07D233/64 ,  C07D213/56 ,  C07D405/12 ,  C07D417/12 ,  C07D409/12 ,  A61P35/00

Abstract: The present invention relates to new benzo-N-hydroxy amide compounds of formula (I) and pharmaceutically acceptable salts, isomers and prodrugs thereof, which show a significant inhibitory activity on the proliferation of tumor cells and specifically of cancer stem cells.

公开(公告)号：US20180311160A1

公开(公告)日：2018-11-01

申请号：US15770443

申请日：2016-10-28

Applicant: ITALFARMACO SPA

Inventor： Giuseppe COLOMBO ,  Roberta ARTICO ,  Paolo MASCAGNI ,  Maria Valmen MONZANI ,  Silvia PUCCIANTI

IPC: A61K9/10 ,  A61K9/00 ,  A61K47/26 ,  A61K47/10 ,  A61K47/36 ,  A61K47/12 ,  A61K47/02 ,  A61K31/325 ,  A61P21/00 ,  A61P19/02 ,  A61P35/02 ,  A61P7/02

Abstract: Physically and chemically stable oral liquid formulations of Givinostat (Diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride) are disclosed, together with methods for the preparation thereof. Such oral formulations are in the form of aqueous suspensions and contain Givinostat and/or pharmaceutically acceptable salts and/or derivatives thereof, at least a wetting agent and/or at least a density-imparting agent. Such formulations are suitable for oral administration for systemic therapeutic action.